Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SCRI Development Innovations, LLC
With
Aventis Pharmaceuticals
Millennium Pharmaceuticals, Inc.
Upon determination of eligibility, patients will be receive:
* Docetaxel + Bortezomib
Patients with objective responses or stable disease will continue treatment for eight courses or until disease progression is documented.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Prostate cancer, and objective evidence of metastatic disease
Progression while receiving androgen ablation therapy
No previous chemotherapy
Measurable or evaluable disease in conjunction with elevated serum PSA levels
ECOG performance status 0, 1, or 2
Adequate bone marrow, liver and kidney function
Voluntarily provide written informed consent
You may not be if
You cannot participate in this study if any of the following apply to you:
Moderate or severe peripheral neuropathy
Age \< 18 years
Other serious medical conditions that may interfere with protocol therapy
Other active malignancies
history of treatment for other invasive cancers within 3 years
